dc.creatorCagel, Carlos Maximiliano
dc.creatorTesan, Fiorella Carla
dc.creatorBernabeu, Ezequiel Adrian
dc.creatorSalgueiro, María Jimena
dc.creatorZubillaga, Marcela Beatriz
dc.creatorMoretton, Marcela Analía
dc.creatorChiappetta, Diego Andrés
dc.date.accessioned2018-06-08T13:39:56Z
dc.date.accessioned2018-11-06T14:48:59Z
dc.date.available2018-06-08T13:39:56Z
dc.date.available2018-11-06T14:48:59Z
dc.date.created2018-06-08T13:39:56Z
dc.date.issued2017-04
dc.identifierCagel, Carlos Maximiliano; Tesan, Fiorella Carla; Bernabeu, Ezequiel Adrian; Salgueiro, María Jimena; Zubillaga, Marcela Beatriz; et al.; Polymeric mixed micelles as nanomedicines: Achievements and perspectives; Elsevier Science; European Journal Of Pharmaceutics And Biopharmaceutics; 113; 4-2017; 211-228
dc.identifier0939-6411
dc.identifierhttp://hdl.handle.net/11336/47839
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1890671
dc.description.abstractDuring the past few decades, polymeric micelles have raised special attention as novel nano-sized drug delivery systems for optimizing the treatment and diagnosis of numerous diseases. These nanocarriers exhibit several in vitro and in vivo advantages as well as increased stability and solubility to hydrophobic drugs. An interesting approach for optimizing these properties and overcoming some of their disadvantages is the combination of two or more polymers in order to assemble polymeric mixed micelles. This review article gives an overview on the current state of the art of several mixed micellar formulations as nanocarriers for drugs and imaging probes, evaluating their ongoing status (preclinical or clinical stage), with special emphasis on type of copolymers, physicochemical properties, in vivo progress achieved so far and toxicity profiles. Besides, the present article presents relevant research outcomes about polymeric mixed micelles as better drug delivery systems, when compared to polymeric pristine micelles. The reported data clearly illustrates the promise of these nanovehicles reaching clinical stages in the near future.
dc.languageeng
dc.publisherElsevier Science
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1016/j.ejpb.2016.12.019
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0939641116306944
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectCANCER
dc.subjectCENTRAL NERVOUS SYSTEM DISEASES
dc.subjectCLINICAL TRIALS
dc.subjectHIV/AIDS
dc.subjectIMAGING TECHNIQUES
dc.subjectNANOMEDICINES
dc.subjectPHARMACEUTICAL APPLICATIONS
dc.subjectPOLYMERIC MIXED MICELLES
dc.subjectPRECLINICAL STUDIES
dc.titlePolymeric mixed micelles as nanomedicines: Achievements and perspectives
dc.typeArtículos de revistas
dc.typeArtículos de revistas
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución